Thymosin alpha-1: an immunology peptide from the thymus
Prepared by: Research Desk. Sources are linked for verification.
Published 19 October 2026
At a glance
- Type: 28-amino-acid peptide, N-terminally acetylated
- Origin: isolated from calf thymus tissue in 1977
- Research stage: decades of immunology research and clinical trials, mostly outside the US
- Regulatory status: approved under the name thymalfasin in a number of countries, mainly in Asia; not approved by FDA
What thymosin alpha-1 is
Thymosin alpha-1 (Tα1) is a heat-stable, highly acidic peptide of 28 amino acids. It is cut from a larger precursor protein, prothymosin alpha. The synthetic form used in medicines is known by the international non-proprietary name thymalfasin. Despite the similar names, thymosin alpha-1 is unrelated in structure to thymosin beta-4.
Research history
In the 1960s and 1970s, Allan Goldstein and Abraham White studied extracts of thymus tissue, which they called "thymosin fraction 5", to understand how the thymus supports the immune system. In 1977, Goldstein et al. in the Proceedings of the National Academy of Sciences reported the isolation and full amino acid sequence of thymosin alpha-1, describing it as one of several polypeptides in fraction 5 that may take part in the regulation of T cells.
A historical overview by Garaci et al. (2007) describes how research moved from thymus extracts to the synthetic peptide and then to clinical studies combining it with other agents in infectious disease and cancer research.
Mechanisms studied in preclinical work
- Toll-like receptors. A 2023 review by Tao et al. summarises evidence that thymosin alpha-1 interacts with several Toll-like receptors (TLR2, TLR3, TLR4, TLR7 and TLR9) and activates downstream pathways such as NF-κB and IRF3.
- Immune cell function. Cell and animal studies report effects on T cells, dendritic cells, natural killer cells and macrophages, including changes in cytokine production and in the expression of MHC class I molecules.
- Immune modulation. A 2016 review by King and Tuthill reviews its effects on immune function in cell, animal and human studies.
The published research landscape
Thymosin alpha-1 has a long clinical trial record, especially in chronic viral hepatitis and as an add-on in oncology and infection research. Many trials were conducted in China and other Asian countries, and their size and quality vary widely. Systematic reviews have reached mixed conclusions depending on the condition and the quality of the included trials. During the COVID-19 pandemic, several observational studies and small trials were published, again with mixed results and significant methodological limits.
For laboratory researchers, the compound is a tool for studying innate immune signalling and T-cell biology, with a large literature of cell and animal studies to build on.
Regulatory status
- Outside the United States. Thymalfasin has been approved in a number of countries, mainly in Asia, largely for use in chronic hepatitis B.
- United States. Thymosin alpha-1 is not an FDA-approved drug. FDA's page on bulk drug substances that may present significant safety risks lists thymosin alpha-1 among substances whose category 2 nominations were withdrawn, citing possible immunogenicity and peptide-related impurities.
- Research-grade material. Material sold as a laboratory reagent is not a licensed thymalfasin product.
Key terms
- Thymosin fraction 5. A partially purified extract of calf thymus from which several thymosin peptides were isolated.
- Prothymosin alpha. The larger precursor protein from which thymosin alpha-1 is cleaved.
- Toll-like receptors (TLRs). Proteins of the innate immune system that recognise molecular patterns from microbes and trigger signalling.
- Thymalfasin. The international non-proprietary name for synthetic thymosin alpha-1 used in licensed medicines.
Open research questions
- Which receptor interactions are direct and which are downstream effects.
- Why trial results differ so widely between conditions and study designs.
- How the peptide's effects depend on the baseline state of the immune system in each model.
Limitations of the evidence
- The trial record is large but uneven in quality, and many trials are small or open-label.
- Mechanistic findings come mainly from cell and animal models.
- Approvals outside the US are specific to licensed products and conditions and do not extend to research-grade material.
Where researchers source it
Purita is a store that lists Thymosin alpha-1 for laboratory research use only. Its product page carries the label "For Research Use Only. Not for human or animal administration."
Affiliate disclosure: this is a paid link. PeptideDiscoveryAI earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.